Amylyx Pharmaceuticals, Inc. Logo

Amylyx Pharmaceuticals, Inc.

Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.

AMLX | US

Overview

Corporate Details

ISIN(s):
US0321085088
LEI:
Country:
United States of America
Address:
43 THORNDIKE STREET, 2141 CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company dedicated to discovering and developing novel treatments for neurodegenerative diseases and other conditions with high unmet medical needs. The company advances a pipeline of investigational therapies based on rigorous science and well-defined mechanistic rationale. Key areas of focus in its pipeline include Amyotrophic Lateral Sclerosis (ALS), Wolfram syndrome, and Post-Bariatric Hypoglycemia. Amylyx is committed to a patient-centric approach, aiming to provide solutions for some of medicine's most complex challenges.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Amylyx Pharmaceuticals, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Amylyx Pharmaceuticals, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Amylyx Pharmaceuticals, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland
SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden
SPRINT
SPRUCE BIOSCIENCES, INC. Logo
Developing first-in-class therapies for serious, underserved neurological conditions like MPS IIIB.
United States of America
SPRB
Spyre Therapeutics, Inc. Logo
Engineering advanced antibody therapies for IBD and other immune diseases.
United States of America
SYRE
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany
SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden
STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea
052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan
4888
StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark
STENO

Talk to a Data Expert

Have a question? We'll get back to you promptly.